Q2 FY2026 · ended Jun 30, 2026 · Revenue $3,000, -57.1% YoY · Filed Aug 7, 2026
Impact BioMedical, INC. (IBO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $3,000 and a net loss of $699,000.
Revenue
$3,000
-57.1% vs year-ago quarter
Net income
$-699,000
+95.1% vs year-ago quarter
Operating cash flow
$470,000
+167.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
+99.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
107.82M
+784.8% vs year-ago quarter
Net cash
—
Operating margin
-14591.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- West Henrietta, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1834105
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3,000 | $7,000 | $7,000 | $18,000 | $7,000 |
| Operating income | -$702,000 | -$2.3M | -$1.2M | -$948,000 | -$1.2M |
| Net income | -$699,000 | -$2.3M | $5.2M | -$1.5M | -$14.3M |
| Diluted EPS | -$0.01 | -$0.02 | — | -$0.12 | -$1.18 |
| Operating cash flow | $470,000 | -$464,000 | $99,000 | -$613,000 | -$694,000 |
| Total assets | $16.7M | $17.1M | $17.4M | $18.2M | $19.1M |
| Total liabilities | $2.7M | $2.4M | $1.9M | $27.1M | $26.4M |
| Stockholders' equity | $10.8M | $11.5M | $12.3M | -$11.8M | -$10.3M |
| Cash and investments | $10,000 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 9, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 146 Impact BioMedical, INC. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.